Trial Profile
Study to determine causes of treatment failure and key resistance associated substitutions to hepatitis C virus (HCV) genotype 1 treated with boceprevir and telaprevir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2018
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 May 2018 New trial record
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases